Unknown

Dataset Information

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?


ABSTRACT:

Unlabelled

Serious adverse events of infections that occurred in subjects receiving denosumab or placebo in the Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were examined in detail. Serious adverse events of infections in denosumab subjects had heterogeneous etiology, with no clear clinical pattern to suggest a relationship to time or duration of exposure to denosumab.

Introduction

Denosumab reduces the risk for new vertebral, hip, and nonvertebral fractures compared with placebo. In the pivotal phase 3 fracture trial (FREEDOM), the overall safety profile and incidence of adverse events including adverse events of infections were similar between groups. Serious adverse events of erysipelas and cellulitis were more frequent in deno

SUBMITTER: Watts NB 

PROVIDER: S-EPMC3249159 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature